In the current issue of the OncoWuXi Newsletter, we would like to share with you our platform for STING related assays and updates on KRAS relevant models. Other interesting topics covered in this issue include newly developed HER2 positive breast cancer PDX models and the recent developments in WuXi in vitro immunology assay platform.
 
OncoWuXi Newsletter will continue to keep you up-to-date with our recent progress in cancer research. As part of WuXi Research Service Division (RSD), our topnotch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

Immuno-Oncology

(1)  Biology background of STING
  • STING signaling pathway
  • Summary of current industrial pipelines on STING agonists
(2)   In vitro cellular functional assay for STING pathway
  • STING agonist stimulation on PBMCs and human THP1 cells, using production of IFNβ as readout
(3)  Cytokine analysis of B16F10 model post STING agonist treatment
  • IL-6 and TNF-α level in plasma
  • IL-6, TNF-α, IFN-γ, MCP-1, IL-12 and IFN-β level in tumor
(4)  In vivo anti-tumor efficacy study of STING agonist in B16F10, 
      CT26, and 4T1 models
(5) Immune cell activation analysis in TILs and spleen in B16F10 
      model post STING agonist treatment



(1) T cell activation by Antibody/SEB/CMV recall
(2) B cell activation
(3) NK cell activation/expansion
(4) T helper cell polarization: Th1, Th2, Th17 and Treg
(5) M1 and M2 macrophage differentiation
(6) DC differentiation
(7) CTL cytotoxicity assay: OT-1 T cell-OVA system
(8) NK cytotoxicity assay using NK-92MI cells
(9) ADCC assay using purified primary NK cells
(10) Mixed lymphocyte reaction: DC-T cell co-culture
(11) MDSC suppressive assay: MDSC-T cell co-culture
(12) Treg suppressive assay: Treg-Teff cell co-culture
(13) Tumor cell suppressive assay: Hela-T cell co-culture
(14) STING pathway activation
(15) NLRP3 inflammasome activation

Targeted Oncology

(1)  KRAS background as a drug target
  • KRAS biology
  • Role of KRAS mutation in cancer
  • KRASG12C inhibitors under development
(2)    CDX models with KRAS mutations
  • Mia-pa-ca 2 pancreatic cancer CDX model with KRASG12Cmutation, validated with AMG 510 and ARS-1620
  • NCI-H358 NSCLC CDX model with KRASG12C mutation, validated with AMG 510 and ARS-1620
  • 21 additional CDX models with various KRAS mutations for 8 cancer types
  • 2D vs 3D CTG validation of AMG510 on NCI-H358 and Mia-pa-ca-2 cell lines  
(3)  PDX models with KRAS mutations
  • 125 PDX models carrying KRASG12C, KRASG12D and other major KRAS mutants, covering 10 cancer types
  • 2 KRASG12C NSCLC PDX models, validated with ARS-1620


(1) Overview of breast cancer and HER2
(2) HER2 positive breast cancer PDX models

Read More


 

We sincerely appreciate your interest, time and support, and would like to hear your feedback so we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

 
Best regards,
WuXi AppTec OncoWuXi Team
        
For more information, please visit
www.wuxiapptec.com